We are live on
!
Find out more
Jacobs Levy Equity Management Portfolio holdings
AUM
$23.8B
1-Year Est. Return
25.4%
This Fund
S&P 500
This Quarter
Est. Return
+9.96%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$25.2B
AUM Growth
-$335M
(-1.3%)
Cap. Flow
-$2.05B
Cap. Flow
% of AUM
-8.13%
Top 10 Holdings %
Top 10 Hldgs %
26.87%
Holding
1,147
New
127
Increased
298
Reduced
504
Closed
194
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$160M |
| 2 |
Masco
MAS
|
+$134M |
| 3 |
Lam Research
LRCX
|
+$112M |
| 4 |
Coupang
CPNG
|
+$101M |
| 5 |
Nu Holdings
NU
|
+$98.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GE Vernova
GEV
|
+$205M |
| 2 |
Lennox International
LII
|
+$191M |
| 3 |
NVIDIA
NVDA
|
+$169M |
| 4 |
Tractor Supply
TSCO
|
+$157M |
| 5 |
Apple
AAPL
|
+$151M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.69% |
| 2 | Consumer Discretionary | 12.85% |
| 3 | Industrials | 12.71% |
| 4 | Financials | 12.68% |
| 5 | Healthcare | 9.5% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RHLD
751
Resolute Holdings Management
RHLD
$1.1B
| $830K | ﹤0.01% |
11,497
-7,597
| -40% | -$411K |
|
752
Jack Henry & Associates
JKHY
$11.2B
| $829K | ﹤0.01% |
5,567
| – | – |
|
753
DexCom
DXCM
$28.9B
| $823K | ﹤0.01% |
12,227
-1,360,740
| -99% | -$108M |
|
754
LifeVantage
LFVN
$81.1M
| $814K | ﹤0.01% |
83,703
-4,752
| -5% | -$59.5K |
|
755
Caribou Biosciences
CRBU
$148M
| $813K | ﹤0.01% |
349,083
-607,897
| -64% | -$1.15M |
|
756
Business First Bancshares
BFST
$1.05B
| $811K | ﹤0.01% |
34,361
+1,606
| +5% | +$39.7K |
|
757
Crexendo
CXDO
$223M
| $805K | ﹤0.01% |
+123,829
| New | +$767K |
|
758
PrimeEnergy Resources
PNRG
$292M
| $802K | ﹤0.01% |
4,802
-1,483
| -24% | -$241K |
|
759
Janus International
JBI
$732M
| $798K | ﹤0.01% |
80,852
| – | – |
|
760
CuriosityStream
CURI
$145M
| $797K | ﹤0.01% |
+150,389
| New | +$693K |
|
761
Carrier Global
CARR
$52.5B
| $787K | ﹤0.01% |
13,184
-159,883
| -92% | -$10.9M |
|
762
8x8 Inc
EGHT
$271M
| $780K | ﹤0.01% |
367,859
+105,224
| +40% | +$212K |
|
|
BBNX
763
Beta Bionics
BBNX
$704M
| $775K | ﹤0.01% |
+38,991
| New | +$685K |
|
764
Superior Group of Companies
SGC
$202M
| $774K | ﹤0.01% |
72,184
-31,851
| -31% | -$365K |
|
765
Pitney Bowes
PBI
$2.41B
| $761K | ﹤0.01% |
66,705
-3,410
| -5% | -$39.7K |
|
766
Purple Innovation
PRPL
$35.7M
| $757K | ﹤0.01% |
+32,418
| New | +$758K |
|
|
HNGE
767
Hinge Health
HNGE
$5.82B
| $743K | ﹤0.01% |
+15,142
| New | +$792K |
|
768
GeneDx Holdings
WGS
$1.84B
| $737K | ﹤0.01% |
6,843
-5,622
| -45% | -$613K |
|
769
NB Bancorp
NBBK
$1.01B
| $737K | ﹤0.01% |
41,766
-7,793
| -16% | -$143K |
|
770
Praxis Precision Medicines
PRAX
$8.25B
| $737K | ﹤0.01% |
13,898
-31,184
| -69% | -$1.51M |
|
771
CrowdStrike
CRWD
$185B
| $717K | ﹤0.01% |
5,848
+2,204
| +60% | +$251K |
|
772
Tredegar Corp
TG
$263M
| $713K | ﹤0.01% |
+88,850
| New | +$732K |
|
773
Viking Holdings
VIK
$46.6B
| $686K | ﹤0.01% |
+11,040
| New | +$658K |
|
|
SNDK
774
Sandisk
SNDK
$162B
| $679K | ﹤0.01% |
+6,050
| New | +$353K |
|
|
SEPN
775
Septerna Inc
SEPN
$1.53B
| $673K | ﹤0.01% |
+35,778
| New | +$470K |
|
Similar funds
OAG
CHP
SAM
JG
Jacobs Levy Equity Management's Q3 2025 Portfolio in Review
As of Q3 2025, Jacobs Levy Equity Management held 1,147 positions worth $25.2B, down 1.3% from $25.5B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Jacobs Levy Equity Management withdrew a net $2.05B in Q3 2025, closing 194 positions and reducing 504 holdings. Its most notable exit was Progressive, an estimated $66.7M position sold in full.
By sector, the portfolio is most concentrated in Technology at 34% of assets, up from 32% a quarter earlier, followed by Consumer Discretionary and Industrials.
Against the trend, Jacobs Levy Equity Management opened a new position in Bank of America worth $45M.
- Jacobs Levy Equity Management's largest Q3 2025 buy was Bank of America: 873,228 shares worth $45M.
- Jacobs Levy Equity Management added most to Alnylam Pharmaceuticals in Q3 2025, an estimated $160M increase.
- Jacobs Levy Equity Management's biggest Q3 2025 reduction was GE Vernova, cutting an estimated $205M.
- Jacobs Levy Equity Management fully exited Progressive in Q3 2025, selling an estimated $66.7M.
- Jacobs Levy Equity Management's ten largest holdings make up 27% of its $25.2B portfolio in Q3 2025.
- Jacobs Levy Equity Management opened 127 new positions and closed 194 in Q3 2025.
- Jacobs Levy Equity Management's portfolio value fell 1.3% quarter-over-quarter to $25.2B.
Based on Jacobs Levy Equity Management's 13F filing for Q3 2025, filed 17 Nov 2025.